Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients

• Status: Withdrawn
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Positive COVID19 test

• Admission to hospital without immediate plans for Intensive Care Unit transfer

• Age >/= 19 y.o.

Exclusion Criteria:

• Allergic reaction to tranexamic acid

• History or active evidence of hypercoagulation disorders including but not limited to deep vein thrombosis, pulmonary hypertension, diffuse intravascular coagulopathy

• Preadmission anticoagulation

• History of GI bleeding

• History of seizures

• Cardiac or other vascular stents

• History of severe renal disease

• History of intracranial hemorrhage